CTI BioPharma

CTI was founded on the belief that a coalition between unique scientific technology and its strong desire to “do right” by the patient could help us achieve our mission to acquire, develop and bring to market less toxic, more effective therapies to treat and cure cancer. We strive to do business better than other biopharmaceutical companies. Better means a more collaborative, well-trained team environment willing to institute novel approaches to scientific discovery and business opportunities. A willingness to push the limits to achieve challenging goals is the essential attribute that sets CTI employees apart.
Type
Public
HQ
Seattle, US
Founded
1992
Employees
149 (est)
CTI BioPharma was founded in 1992 and is headquartered in Seattle, US

CTI BioPharma Locations

Seattle, US

CTI BioPharma Metrics

CTI BioPharma Summary

Market capitalization

$138 M

Closing share price

$0.485
CTI BioPharma's latest market capitalization is $138 M.

CTI BioPharma Financials

CTI BioPharma's revenue was $16.1 M in FY, 2015 which is 73.17% decrease from the previous period.
FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015

Revenue

$319 K$34.7 M$60.1 M$16.1 M

Cost of goods sold

$137 K$895 K$1.94 M

Gross profit

$34.5 M$59.2 M$14.2 M

Gross profit Margin, %

99.6%98.5%88.0%

CTI BioPharma Market Value History

CTI BioPharma News

CTI BioPharma Company Life

You may also be interested in